| This week's sponsor is PPD. |
 |
|
Click here to download the whitepaper.
|
Today's Top Stories
1.
Bayer settles Yasmin suits for $212K each, $402M total
2.
Lupin eyes buyouts up to $500M in U.S. growth push
3.
Proxy firm backs half of Icahn's Forest nominees
4.
U.K. drug spending down, scripts up on 'patent dividend'
5.
Shire, UCB see new-drug growth as Allergan, Hospira fall short
Editor's Corner:
The top 15 biotech venture investments in H1 2012
Also Noted: Catalent
Spotlight On...
Can retooled Pfizer deliver on R&D promises?
GSK may be target of Anonymous hackers; Bristol says anti-trust wait over for Amylin deal; Daiichi Sankyo says its loves social IT tool;
and much more...
More Fierce Life Sciences News:
1.
UPDATED: Adimab, Mersana strike deal to make antibody-drug combos for pharma
2.
Olympics anti-doping team to pursue biomarkers after the games
3.
Olympus slapped with DOJ inquiries, Terumo shareholder lawsuit
| This week's sponsor is IMS Health. |
 |
IMS VOICE™ connects in one framework the treatment of conditions in facilities with an estimate and ranking of the physicians who are performing the procedures of interest within those facilities. Click here to learn more about IMS VOICE.
|
|
The top 15 biotech venture investments in H1 2012
 Perhaps it's no surprise that much of the top venture investment for the first half of 2012 was delivered by the VC arm of billionaire Randal Kirk to his biotech venture Intrexon. These days, it's good to have your own money to bank on when you're growing a biotech company.
It's also extraordinarily rare.
The first half of the year delivered a long string of red flags on the venture side of the business. Startups were finding it harder than ever to gain new rounds as investing plunged in the second quarter of the year. And that same bottom line was reached by every group that crunches the numbers.
Over the last quarter biotech companies scraped together $697 million in 90 deals, a stinging 42% drop compared to the same period a year ago and the lowest level the National Venture Capital Association--which got its numbers from Thomson Reuters--has seen since the first quarter of 2003.
Which doesn't mean there isn't a silver lining. The buyout deals struck in recent months--Amylin and Human Genome Sciences, for example--show that Big Pharma is still finding many of its best new products in companies it can easily afford to buy. With AstraZeneca ($AZN) and others anxious to grow pipelines, willing to license what they won't buy, you can look for more deals in the future. And as long as such buyers are out there, new biotechs will be coming around to look for a deal.
The following 15 venture rounds qualified as the top investments of the first half, as tracked by Thomson Reuters and the National Venture Capital Association. At first glance, you may wonder where the figures come from. FierceBiotech runs the rounds as they're touted by the companies. The NVCA tracks actual dollars that are flowing to the company in a designated time period. So Tesaro ($TSRO), which announced a $101 million round of venture funding last year, got the bulk of that in a second tranche in the first half. Warp Drive Bio, which announced a $125 million Series A in January, actually landed $75 million last December. Click here to view the top 15 venture investments in H1 2012 >> -- John Carroll, Editor-in-Chief. Follow me on Twitter and LinkedIn.
Read more about: Biotech Venture Capital
back to top
|
|
|
Sponsor: Akamai
Events
> Drug, Device and Food Law & Regulation Conference - September 10-11 - Brazil
> Pharma CI Conference - September 11-12 - Parsippany, NJ
> Second Asia Pacific Pharma Compliance Congress - September 11-12 - Shanghai, China
> BioImmersion Course from BioTech Primer Inc. - September 26-28 - Washington, D.C.
> First Latin American Pharmaceutical Compliance Congress - October 2-4 - Sao Paulo, Brazil
> The Universe of Pre-filled Syringes & Injection Devices - October 15-17, 2012 - Las Vegas, Nevada (Red Rock Resort and Spa)
> Master the evolving healthcare environment and deliver accuracy - October 16-17 - Woodbridge, NJ, USA
> Thirteenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum - November 5-7 - Washington, DC
> PDA/FDA Pharmaceutical Supply Chain Conference - November 13-14 - Bethesda, MD (Bethesda North Marriott Hotel)
> Real World Data & Health Outcomes - November 29-30 - Boston, MA
Marketplace
> Research: Special Report: Cancer Immunotherapy Production: Overcoming Obstacles to Profitability
> Research: Generic Defense Strategies
> Research: Treatment Algorithms: Colon Cancer - Treatment dictated by stage, prior therapy, and reimbursement
> Research: Treatment Algorithms: Rectal Cancer - Inclusion of chemoradiation can influence treatment and prescribing trends
> Research: R&D Trends: Non-Small Cell Lung Cancer - Mutation analyses continue driving treatment choices
> EBook: The Right Fix: How Patient- Centric Data is Driving ROI and Revolutionizing the World of Pharmaceutical marketing
Jobs
> Sr. Clinical Document Processor Job - Summit, NJ, US - Celgene Corporation
> Hematology Oncology Consultant, Hematology - San Jose Job - San Jose , CA, US - Celgene Corporation
> Hematology Oncology Consultant, Hematology - Canton/Akron Job - Canton, OH, US - Celgene Corporation
> Biostatistician - Permanent Job - Concord, CA, USA – Yoh
> Purification Bulk Support Associate Scientist Job - Holly Springs, NC, USA – Yoh
> Postdoctoral Scientist Job - Lexington, MA, USA – Yoh
> Bench Scientist II Job - King of Prussia, PA, USA – Yoh
> Manager, Sales Operations – Data Job - Basking Ridge, NJ, US – Celgene Corporation
> Scientist/Senior Scientist – Biochemistry - Cambridge MA - Catabasis Pharmaceuticals, Inc.
> Pharma Field Sales - Diabetes Care Specialist (DCS) - Portland, OR, US – Novo Nordisk
> Pharma Field Sales - Diabetes Care Specialist (DCS) - McKinney, TX, US – Novo Nordisk
> Need a job? Need to hire? Visit FiercePharma and Biotech Jobs
* Post a classified ad: Click here.
* General ad info: Click here
|
Today's Top News
1.
Bayer settles Yasmin suits for $212K each, $402M total
That €500 million ($615.8 million) that Bayer set aside to cover its Yaz and Yasmin litigation? A big chunk of it is already spent. The company said it has settled almost 1,900 lawsuits for a total of $402 million-plus. That's an average of about $212,000 per case.
The lawsuits involve allegations that the birth control pills, which include the synthetic hormone drospirenone, caused blood clots. Studies have raised red flags about the clot risks over the years, but Bayer has said its own data doesn't show that its products are appreciably more risky than other contraceptive pills. Hormonal birth control is known to increase the incidence of blood clots, particularly in smokers. In April, however, FDA asked Bayer to amp up blood-clot warnings on its drospirenone products.
The €500 million comes on top of €200 million ($246.3 million) set aside in 2010 and 2011, Bloomberg reports, a total of about $862 million at today's exchange rates. "We believe we have made appropriate provisions for most of the cases we consider to be worthy of settlement with these accounting measures," the company said (as quoted by the news service).
Analysts aren't so sure; some have said Bayer could end up shelling out more than €2 billion ($2.46 billion) to wrap up all the Yasmin-and-its-sisters lawsuits. When the FDA warnings were announced, Bayer had about 11,900 suits outstanding; at the time, the company had settled about 651 cases. The birth-control pills brought in $1.1 billion in sales last year.
- see the Bloomberg coverage
Related Articles:
Bayer profits hit by $500M charge for Yaz/Yasmin lawsuits
Bloomberg: Bayer to pay $110 million to get out from under 500 Yaz lawsuits
FDA adds clotting data to Bayer's Yaz, Yasmin
Yaz plaintiffs ask judge to weigh alleged FDA conflicts
Read more about: birth control
back to top
|
| This week's sponsor is Akamai. |
 |
"Leveraging Cloud Security to Weather Threatening Storms" assesses the current cyber threat environment. Learn how distributed cloud services can be used to protect against modern-day IT threats and gain an in-depth look at DDoS defense. Download Now.
|
2.
Lupin eyes buyouts up to $500M in U.S. growth push
Lupin executives keep talking up their plans for U.S. expansion. Buying brands, buying companies, pumping up its own launches of generic drugs--the Indian drugmaker says it's going to pull out all the stops to build up its stateside presence.
It's all about improving margins and positioning itself for long-term growth after the biggest patent-cliff years are past. Generics are Lupin's staple, and it's aiming to reap as much growth from the newly off-patent blockbusters as it can. But its branded drugs deliver a much greater portion of sales to the bottom line, so adding to that business is a key goal. On the generics side, Lupin is looking toward products that aren't as commoditized as the garden-variety generic, and as such enjoy bigger margins.
For a hint of what sort of companies Lupin might be interested in snapping up, consider this: It shopped ISTA Pharmaceuticals, the eye drug specialist, before Bausch & Lomb agreed to buy it for $500 million. As The Wall Street Journal points out, that's a much bigger buyout than Lupin has ever engineered in the U.S.
Apparently, though, Lupin is willing to sock that kind of money into a U.S. deal. The company sources about 35% of its sales in the States now, and sees the U.S. as its primary growth market. Preferred therapeutic areas include dermatology, ophthalmology, respiratory and women's health. "We've looked at small-sized acquisition opportunities as well as opportunities in the $400 million-$500 million price range," group president Vineeta Gupta has said (as quoted by the WSJ).
- read the WSJ piece
Related Articles:
India's Lupin shops for U.S. brands to bolster margins
Lupin expands Japanese reach with I'Rom buy
Lupin said to weigh sale of Indian pharma unit
Medicis inks $58M dermatology pact with India's Lupin
Read more about: Generic drugs
back to top
|
3.
Proxy firm backs half of Icahn's Forest nominees
4.
U.K. drug spending down, scripts up on 'patent dividend'
Want a statistical representation of the patent cliff's decidedly mixed blessings? The U.K. just released its latest report on drug spending. The gist is, costs are down but prescription numbers are up. And that's because more patients are using cheap generics as branded drugs go off patent.
The number of dispensed prescriptions grew to 961.5 million last year in the U.K., an increase of 3.8%. Their costs dropped by 0.3%, however, to £8.8 billion, or $13.8 billion.
So, clearly the patent cliff is helping the National Health Service's budget, and, as Reuters points out, British taxpayers. It's also pumping up sales for generics makers. But as pharma earnings this quarter have so dramatically spelled out, it's murder on branded sales.
But let's focus on the positive for a moment. As Reuters reports, payers see patent expirations as a boon--a big-time, multibillion-dollar boon. IMS Health figures that expiring patents in developed countries will save governments and other payers some $106 billion over the five years ended 2016, Reuters points out. Branded spending over that timeframe will plummet by $127 billion, while generics spending will increase by $21 billion.
The good news for branded pharma? The shrinking share of branded drugs in the U.K. could actually aid adoption of new drugs as value-based pricing nears, Reuters notes. If branded meds aren't racking up big growth, then the government might be more reasonable about setting prices and introducing newly minted products.
- read the Reuters article
Related Articles:
Beware: Patent losses to climb back to $56B by 2015
Who'll be the biggest drugmaker of them all?
Analysts: CMO market will double by 2018
Read more about: patent expirations
back to top
|
5.
Shire, UCB see new-drug growth as Allergan, Hospira fall short
There's a bumper crop of numbers today as pharma's earnings season winds down. The dominant trends continue--the stronger dollar, generic competition (for branded drugmakers), new copycat products (for generics firms) and lots of expectations-management.
-
One company whose results didn't depend on these developments, however, was Hospira ($HSP). Quality control problems pushed the company into the red. Costs and charges stemming from product recalls and manufacturing fixes weighed on profits; sales were down, too. Report
-
Allergan's ($AGN) sales and earnings grew, but sales fell short of analyst estimates, partly because of currency effects. It updated its revenue forecast with lower-than-expected numbers, too. The company did manage to post street-beating earnings at $1.07 per share. Report
-
Shire was upbeat about new Adderall copycats--and upbeat about the year overall. The company affirmed expectations for a double-digit increase in earnings as it surpassed expectations for the quarter. "[W]e believe that branded Adderall XR will remain competitive in the U.S. marketplace despite the approval of a new generic product," Shire said. Report
-
Meanwhile, Impax Laboratories ($IPXL) posted higher-than-expected earnings--60 cents versus 45 cents--aided by sales of... generic Adderall XR. Growth of its migraine drug Zomig helped, too. Sales grew to $162 million. Report
-
Belgium's UCB saw sales of its seizure drug Keppra drop by 12% on generic competition in the U.S., but growth in other products helped offset that decline. Cimzia (rheumatoid arthritis) grew by 46% to €209 million ($257.1 million), while another seizure drug, Vimpat, grew by 54% to €150 million ($184.5 million). The Neupro patch grew 20% to €54 million ($66.4 million). CEO Roch Doliveux figures these three products will hit €3.1 billion ($3.8 billion) after 2015. Report
Related Articles:
Shire CEO sees consumer-goods strategies in pharma's future
Hospira blames supplier's bad vials for latest recall
Impax licenses U.S. rights to AstraZeneca migraine drug, variations likely
Read more about: UCB Pharma, Allergan
back to top
|
Also Noted
SPOTLIGHT ON...
Can retooled Pfizer deliver on R&D promises?
Pfizer ($PFE) CEO Ian Read is long on promises of a sunny R&D future. But its near-term pipeline offers iffy benefits, and Read hasn't clearly outlined his approach to juggling internal research with buying and licensing prospective products. Report
 @FiercePharma: Patent cliff news that's good for the NHS, not so much for pharma: U.K. scripts up, costs down--Reuters. More | Follow @FiercePharma
> The IT security firm Radware says GlaxoSmithKline ($GSK) is among targets that the computer hacking group Anonymous intends to hit during the Olympics. Story
> As Johnson & Johnson ($JNJ) is gets plant problems under control and plans to relaunch tin coming months the consumer products that have been out of stock, there is evidence consumers have moved on to other, often cheaper, products. Story
> Bristol-Myers Squibb ($BMY) says the waiting period under the Hart-Scott-Rodino Antitrust provisions has expired paving its way to complete its $7 billion acquisition of Amylin. Release
> Pharmacy benefit manager Express Scripts has tapped drug wholesaler AmerisourceBergen over Cardinal Health to be its distribution partner in a three-year supply deal, worth $18.5 billion annually. Story
> Vertex Pharmaceuticals ($VRTX) had its shares downgraded by a variety of analysts including Piper Jaffray, UBS and Bank of America, while analysts at Needham & Company reiterated a "buy" rating, on the company which in May had to acknowledge it had mistakenly announced flawed clinical results on how its cystic fibrosis drug Kalydeco worked with another therapy. Story
Medical Device News
@FierceMedDev: Cool science news: researchers have developed a mechanosensor that could be used for biomed sensing and artifical skin. More | Follow @FierceMedDev
@MarkHFierce: The use of transcatheter aortic valve implants may be based on shaky evidence. More | Follow @MarkHFierce
@DamianFierce: After closing its $241 Medtox acquisition, LabCorp denies it's a buyout target. Article | Follow @DamianFierce
> New flexible sensor tech mulled as basis for artificial skin. News
> Olympus slapped with DOJ inquiries, Terumo shareholder lawsuit. Article
> Affymetrix posts boosts in revenue, income after acquisition. Story
> ADHD-treating video game charts novel approval path. More
Biotech News
@FierceBiotech: Medidata lands record $100M deal with a Big Pharma. More | Follow @FierceBiotech
@JohnCFierce: Can a new Pfizer find success in its long-struggling R&D division? More | Follow @JohnCFierce
@RyanMFierce: Call me skeptical. Moncef Slaoui wants to jump-start pharma innovation, use bioelectronics to treat disease. More | Follow @RyanMFierce
> The top 15 biotech venture investments in H1 2012. Report
> Adimab, Mersana strike deal to make antibody-drug combos for pharma. News
> Buzz: Avalon Ventures passes the hat on $200M biotech fund. Article
> Can a new Pfizer find success in its long-struggling R&D division? More
> Pfizer faces delay on tofacitinib as new data adds blockbuster luster. Story
Drug Delivery News
> $27M funding will help advance Mersana's ADC pipeline. Story
> InSite Vision starts Phase III for post-surgery eye pain treatment. Article
> Israeli government invests $11M in nanodelivery. News
Biomarkers News
> GSK to leave phenomenal Olympic legacy for biomarker research. News
> LifeCodexx gets go ahead for Down syndrome test in Switzerland. Story
> Genetic mutation behind rare childhood paralysis. Article
> Gene fusion signposts aggressive brain cancer. More
And Finally... The U.K. division of Japanese pharma company Daiichi Sankyo says the internal social networking tool Chatter has not only revolutionized employee communication but also its relationship with customers. Story
> Drug, Device and Food Law & Regulation Conference - September 10-11 - Brazil
The Food and Drug Law Institute’s event in Brazil is an exclusive opportunity to hear from ANVISA and FDA officials. The conference will focus on business opportunities and policy challenges of producing products and promoting public health. Register now.
> Pharma CI Conference - September 11-12 - Parsippany, NJ
The Pharma CI Conference & Exhibition is THE INDUSTRY'S GOLD STANDARD for senior level pharmaceutical, biotechnology, medical device, and diagnostics professionals seeking the latest news and the rare chance to network with all the industry's luminaries. 75+ speakers at the industry's best and biggest gathering of pharma competitive intelligence professionals. More than 300 people came in 2011!
> Second Asia Pacific Pharma Compliance Congress - September 11-12 - Shanghai, China
The Congress, sponsored by Asia Pacific Healthcare Industry Compliance Team and Pharmaceutical Compliance Forum, features China compliance officer panel, a faculty of over 50 experts and coverage of compliance issues across Asia. Learn more.
> BioImmersion Course from BioTech Primer Inc. - September 26-28 - Washington, D.C.
Understand the key science, applications and terminology in your industry. This three-day course delivers an in-depth understanding of both fundamental and advanced biotechnology concepts used in both biotech and pharma companies. Register today!
> First Latin American Pharmaceutical Compliance Congress - October 2-4 - Sao Paulo, Brazil
The Congress, sponsored by Latin American Ethics and Compliance Network and Pharmaceutical Compliance Forum, features IFPMA code workshop, anticorruption, disclosure, compliance issues in JVs and M/A and a faculty of over 60 experts and coverage of compliance issues across Latin America. Learn more.
> The Universe of Pre-filled Syringes & Injection Devices - October 15-17, 2012 - Las Vegas, Nevada (Red Rock Resort and Spa)
Our industry is entering a challenging phase for the next decade. While increasing development costs and regulatory demands exert downward pressure on our ability to rapidly introduce devices that are safe and effective, we simultaneously face the expanding needs of a diverse and aging patient population. To address these challenges, it is crucial to continue on the path of innovation. Join PDA for our signature conference on The Universe of Pre–filled Syringes & Injection Devices.
> Master the evolving healthcare environment and deliver accuracy - October 16-17 - Woodbridge, NJ, USA
Our 6th annual forecasting summit will get you on top of a changing regulatory and payer environment. How the Affordable Care Act will affect pipeline & product forecasting, Get the complete guide to master new product forecast strategy, Learn to create and effectively integrate forecasts which meet leadership requirements. Find out more. Click here
> Thirteenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum - November 5-7 - Washington, DC
The Pharma Congress, sponsored by Pharmaceutical Compliance Forum, features OIG Counsel Demske and Riordan, Qui Tam, AUSA, State prosecutor and Sunshine panels, and a faculty of over 100 national and global compliance experts. Learn more.
> PDA/FDA Pharmaceutical Supply Chain Conference - November 13-14 - Bethesda, MD (Bethesda North Marriott Hotel)
The challenge of securing and protecting the integrity of the vast, global pharmaceutical supply chain can be met through a variety of science and risk-based approaches. Building on earlier PDA co-sponsored conferences, the PDA/FDA Pharmaceutical Supply Chain Conference will provide participants with a forum to further discuss innovative approaches aiming to prevent illicit acts such as counterfeiting, diversion and economic adulteration from threatening the safety of the drug supply.
> Real World Data & Health Outcomes - November 29-30 - Boston, MA
Use data to deliver robust evidence for the value of your drugs. This two day conference will explore the opportunities for pharma, with industry, regulator, academic and payer presentations, workshops and networking sessions. Learn more.
|
> Research: Special Report: Cancer Immunotherapy Production: Overcoming Obstacles to Profitability
Preventative vaccines have changed the face of infectious disease, even leading to the near eradication of polio. Now therapeutic vaccines are looking to change the treatment of cancer and other diseases. The science is exciting and the results are positive. But the challenges of manufacturing cancer vaccines could risk making this an impractical solution to an already complex problem. Download the report today.
> Research: Generic Defense Strategies
An overview of developmental, commercial and legal lifecycle management strategies used by pharma to protect their franchises from generic competition. Learn more.
> Research: Treatment Algorithms: Colon Cancer - Treatment dictated by stage, prior therapy, and reimbursement
This report provides analysis of current treatment dynamics of colon cancer. Based on Datamonitor’s survey of 126 oncologists and cancer treaters the report assesses treatment type, prescribing influences, and patient numbers across disease stages. Learn more.
> Research: Treatment Algorithms: Rectal Cancer - Inclusion of chemoradiation can influence treatment and prescribing trends
This report provides analysis of current treatment dynamics of rectal cancer. Based on Datamonitor’s survey of 127 oncologists and cancer treaters the report assesses treatment type, prescribing influences, and patient numbers across disease stages. Learn more.
> Research: R&D Trends: Non-Small Cell Lung Cancer - Mutation analyses continue driving treatment choices
Review of key R&D trends in non-small cell lung cancer (NSCLC) including; dynamics of the pipeline, comparator therapies, target product profile, trends in clinical trial design, innovative early-stage projects, and the future of NSCLC treatment. Learn more.
> EBook: The Right Fix: How Patient- Centric Data is Driving ROI and Revolutionizing the World of Pharmaceutical marketing
Advances in Anonymous Patient Level Data have empowered pharmaceutical marketers to refine their efforts to reach desired customers, accurately monitor the success of their campaigns, and ultimately generate greater ROI. Click here to download today.
|
> Sr. Clinical Document Processor Job - Summit, NJ, US - Celgene Corporation
Celgene Corporation is committed to delivering innovative therapies designed to improve the lives of patients worldwide. Responsibilities includes to develop, implement, and maintain tracking spreadsheet to collect, review, and report metrics. Also to create, maintain, and update customer guidance documents as needed. Minimum 5-10 years word processing experience with expert Microsoft Word, Excel, Outlook and PowerPoint skills...Learn more.
> Hematology Oncology Consultant, Hematology - San Jose Job - San Jose , CA, US - Celgene Corporation
Celgene Corporation is committed to delivering innovative therapies designed to improve the lives of patients worldwide. The Hematology Oncology Consultant is responsible for achieving all territory sales goals through the promotion, sale and support of company products or services in his/her geographic territory. Bachelor's degree in Business or Science; minimum of 5 years' sales experience in the pharmaceutical/biotechnology industry with two years Oncology experience preferred...Learn more.
> Hematology Oncology Consultant, Hematology - Canton/Akron Job - Canton, OH, US - Celgene Corporation
Celgene Corporation is committed to delivering innovative therapies designed to improve the lives of patients worldwide. The Hematology Oncology Consultant is responsible for achieving all territory sales goals through the promotion, sale and support of company products or services in his/her geographic territory. Bachelor's degree in Business or Science; minimum of 5 years' sales experience in the pharmaceutical/biotechnology industry with two years Oncology experience preferred...Learn more.
> Biostatistician - Permanent Job - Concord, CA, USA – Yoh
Yoh has a direct-hire opportunity for a Biostatistician to join our client in Concord, CA. This role will perform statistical analysis and reports for pre-clinical and clinical studies. Ph.D. in Biostatistics or Statistics with a minimum of two years experience or a Master's degree with a minimum of three years experience in the Pharmaceutical / Biotechnology industry required...Learn more.
> Purification Bulk Support Associate Scientist Job - Holly Springs, NC, USA – Yoh
Yoh has a career enhancing contract opportunity for an experienced Purification Bulk Support Associate Scientist to join our premiere client in Holly Springs, NC. The Manufacturing Science and Technology (MS&T) group currently has a position open for manufacturing support of the flu cell culture (FCC) process. The candidate will provide technical support for the downstream (purification) portion of the process to the bulk manufacturing team. Bachelors of Science (BS) in Science or Engineering or equivalent experience required...Learn more.
> Postdoctoral Scientist Job - Lexington, MA, USA – Yoh
Yoh has a career enhancing contract opportunity for an experienced Postdoctoral Scientist to join our premiere client in Lexington, MA. The successful candidate will apply knowledge of bioanalytical methods and enzymology concepts to determine the specific activity and kinetic parameters of enzymes using plate- and LC-based platforms with various detection modes such as pulsed amperometric detection, conductivity, and fluorescence. PhD degree in Analytical Chemistry, Biochemistry, or equivalent experience required...Learn more.
> Bench Scientist II Job - King of Prussia, PA, USA – Yoh
Yoh has a contract opportunity for Bench Scientist II to join our client in King of Prussia, PA. Our client is a science-led global healthcare company. Their mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Responsibilities include to independently conduct GLP and GCP regulated bio-analysis, interpret study data and author draft reports. Experience working in a GLP/GCP environment required...Learn more.
> Manager, Sales Operations – Data Job - Basking Ridge, NJ, US – Celgene Corporation
Celgene Corporation is committed to delivering innovative therapies designed to improve the lives of patients worldwide. In an effort to exceed strategic and operational requirements, the Manager, Sales Operations will support the data process for the US commercial organization. This individual must have extensive industry experience focused on delivering results within the areas of demand reporting, customer master, sales force automation, data warehousing. Minimum of 5 years experience in Sales Operations required...Learn more.
> Scientist/Senior Scientist – Biochemistry - Cambridge MA - Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc. is dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. We are currently looking for a highly motivated, energetic, and relentlessly resourceful individual to join our team as a Scientist or Senior Scientist in our Biochemistry group. The individual will be responsible for the development of enzyme assays using LC-MS/MS as a primary readout. The ideal candidate will have a Ph.D. and 2+ years of industry experience or BS/MS and 5+ years of industry experience...Learn more.
> Pharma Field Sales - Diabetes Care Specialist (DCS) - Portland, OR, US – Novo Nordisk
This position represents Novo Nordisk to large community hospitals and other institutional settings as defined. This position has a goal of maximizing sales and positioning Novo Nordisk as a leader in the diabetes care market, within an assigned territory. The DCS must achieve sales goals by successfully selling and promoting Novo Nordisk's portfolio of diabetes products to key physicians, pharmacists, nurses, and other health care professionals who make or are involved in purchasing, prescribing, and formulary decisions...Learn more.
> Pharma Field Sales - Diabetes Care Specialist (DCS) - McKinney, TX, US – Novo Nordisk
This position represents Novo Nordisk within an assigned territory with the goal of maximizing sales and positioning Novo Nordisk as the leading company in diabetes care. The DCS must assume responsibility for achieving sales goals by implementing marketing and sales strategies aimed at effectively selling and promoting Novo Nordisk's portfolio of diabetes products to physicians, pharmacists, nurses, and other paramedical customers and current co-promotion partners who make or are involved in purchasing and prescribing decisions...Learn more.
> Need a job? Need to hire? Visit FiercePharma and Biotech Jobs
50+ new jobs just posted. Employers now post to the web site free. Find the perfect job or post your openings at FiercePharma Jobs.
|
Refer FiercePharma to a Colleague
Contact Us
Executive Editor: Ryan McBride.
Publisher: Rebecca Friend.
VP, Sales: Jack Fordi.
Advertise
Advertising/Lead-Generation: Jack Fordi. Request a media kit.
Explore our network of publications:
|
